16,16-Dimethyl prostaglandin E2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 41, Issue 1, 2009, Pages 50-58

  Failla, Marco ^a   Genovese, Tiziana ^b,c   Mazzon, Emanuela ^b,c   Fruciano, Mary ^a   Fagone, Evelina ^a   Gili, Elisa ^a   Barera, Annalisa ^a   La Rosa, Cristina ^a   Conte, Enrico ^a   Crimi, Nunzio ^a   Cuzzocrea, Salvatore ^b,c   Vancheri, Carlo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

16,16 dimethyl PGE2; Bleomycin; IPF; Lung fibrosis; Mice

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; 3 NITROTYROSINE; BLEOMYCIN; COLLAGEN; INTERLEUKIN 1BETA; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; 3-NITROTYROSINE; DRUG DERIVATIVE; PEROXIDASE; PROTECTIVE AGENT; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG EDEMA; LUNG FIBROSIS; LUNG FLUID; LUNG INFILTRATE; LUNG INJURY; LUNG LAVAGE; MALE; MORTALITY; MOUSE; NONHUMAN; SURVIVAL RATE; WEIGHT CHANGE; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; PNEUMONIA; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ANIMALIA; MUS;

16,16-DIMETHYLPROSTAGLANDIN E2; ANIMALS; BLEOMYCIN; BODY WEIGHT; BRONCHOALVEOLAR LAVAGE FLUID; COLLAGEN; DISEASE MODELS, ANIMAL; INFUSIONS, SUBCUTANEOUS; INTERLEUKIN-1BETA; LUNG; LUNG INJURY; MALE; MICE; PEROXIDASE; PNEUMONIA; PROTECTIVE AGENTS; PULMONARY EDEMA; PULMONARY FIBROSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 67649241028     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2007-0438OC     Document Type: Article

References (39)

1. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-150.
2. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002;110:651-658.
3. Vancheri C, Mastruzzo C, Sortino MA, Crimi N. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 2004;25:40-46.
4. Ozaki T, Rennard SI, Crystal RG. Cyclooxygenase metabolites are compartmentalized in the human lower respiratory tract. J Appl Physiol 1987;62:219-222.
5. Vancheri C, Sortino MA, Tomaselli V, Mastruzzo C, Condorelli F, Bellistri G, Pistorio MP, Canonico PL, Crimi N. Different expression of TNF-alpha receptors and prostaglandin E(2) production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 2000;22:628-634.
6. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995;95:1861-1868.
7. Bonner JC, Rice AB, Ingram JL, Moomaw CR, Nyska A, Bradbury A, Sessoms AR, Chulada PC, Morgan DL, Zeldin DC, et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol 2002;161:459-470.
8. Lappi-Blanco E, Kaarteenaho-Wiik R, Maasilta PK, Anttila S, Paakko P, Wolff HJ. COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am J Clin Pathol 2006;126:717-724.
9. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol 2004;165:1663-1676.
10. Moore BB, Coffey MJ, Christensen P, Sitterding S, Ngan R, Wilke CA, McDonald R, Phare SM, Peters-Golden M, Paine R III, et al. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandindependent mechanism. J Immunol 2000;165:4032-4039.
11. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
12. Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 2003;29:537-544.
13. Saltzman LE, Moss J, Berg RA, Hom B, Crystal RG. Modulation of collagen production by fibroblasts: effects of chronic exposure to agonists that increase intracellular cyclic AMP. Biochem J 1982;204:25-30.
14. Moore BB, Ballinger MN, White ES, Green ME, Herrygers AB, Wilke CA, Toews GB, Peters-Golden M. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol 2005;174:5644-5649.
15. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005;33:9-13.
16. Parrott RF, Vellucci SV. Effects of centrally administered prostaglandin EP receptor agonists on febrile and adrenocortical responses in the prepubertal pig. Brain Res Bull 1996;41:97-103.
17. Kunikata T, Tanaka A, Miyazawa T, Kato S, Takeuchi K. 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 2002;47:894-904.
18. Cuzzocrea S, Ianaro A, Wayman NS, Mazzon E, Pisano B, Dugo L, Serraino I, Di PR, Chatterjee PK, Di RM, et al. The cyclopentenone prostaglandin 15-deoxy-delta(12,14)- PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 2003;138:678-688.
19. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-470.
20. Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985;14:157-167.
21. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-376.
22. Green FH. Overview of pulmonary fibrosis. Chest 2002;122:334S-339S.
23. Charbeneau RP, Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005;108:479-491.
24. Borok Z, Gillissen A, Buhl R, Hoyt RF, Hubbard RC, Ozaki T, Rennard SI, Crystal RG. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am Rev Respir Dis 1991;144:1080-1084.
25. Ozaki T, Moriguchi H, Nakamura Y, Kamei T, Yasuoka S, Ogura T. Regulatory effect of prostaglandin E2 on fibronectin release from human alveolar macrophages. Am Rev Respir Dis 1990;141:965-969.
26. Petkova DK, Clelland CA, Ronan JE, Lewis S, Knox AJ. Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 2003;43:381-386.
27. Xaubet A, Roca-Ferrer J, Pujols L, Ramirez J, Mullol J, Marin-Arguedas A, Torrego A, Gimferrer JM, Picado C. Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:35-42.
28. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001;158:1411-1422.
29. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB. Protection from pulmonary fibrosis in leukotrienedeficient mice. Am J Respir Crit Care Med 2002;165:229-235.
30. Ohno H, Morikawa Y, Hirata F. Studies on 15-hydroxyprostaglandin dehydrogenase with various prostaglandin analogues. J Biochem 1978;84:1485-1494.
31. Jiang Z, You DY, Chen XC, Wu J. Monitoring of serum markers for fibrosis during CCl4-induced liver damage: effects of anti-fibrotic agents. J Hepatol 1992;16:282-289.
32. Warshamana GS, Corti M, Brody AR. TNF-alpha, PDGF, and TGF-beta(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: TNF-alpha induces TGF-beta(1). Exp Mol Pathol 2001;71:13-33.
33. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994;7:515-518.
34. Conte E, Bonaiuto C, Nesci C, Crimi N, Vancheri C, Messina A. Nuclear factor-kappaB activation in human monocytes stimulated with lipopolysaccharide is inhibited by fibroblast conditioned medium and exogenous PGE2. FEBS Lett 1997;400:315-318.
35. Pan LH, Ohtani H, Yamauchi K, Nagura H. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996;46:91-99.
36. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993;5:57-61.
37. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107:1529-1536.
38. Lawrence RA, Jones RL, Wilson NH. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br J Pharmacol 1992;105:271-278.
39. Kunikata T, Araki H, Takeeda M, Kato S, Takeuchi K. Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes. J Physiol (Paris) 2001;95:157-163.